SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Skeeter Bug who wrote (25628)9/22/1998 9:19:00 AM
From: Henry Niman  Respond to of 32384
 
Here's the intro:
Ligand Pharmaceuticals, Inc. BIOTECHNOLOGY
LGND/FY Ends Dec/$ 7 1/8 HAMBRECHT & QUIST LLC R. van den Broek, CFA (212) 207-1412
Notes: a, b,f SPOT REPORT Jay H. Kim (212) 207-1461
Recommendation: Buy September 21st, 1998
Ligand: Asset Valuation and Near-Term Events
* We expect topical Panretin and ONTAK to be
approved by year end 1998, and for launch to occur
shortly thereafter.
* This report is an except from an industry overview,
"Biotechnology Universe: Asset Valuations", dated Sept.
18, 1998 (pp. 24).



To: Skeeter Bug who wrote (25628)9/22/1998 9:32:00 AM
From: Henry Niman  Read Replies (1) | Respond to of 32384
 
sb, I guess buyers are going to ignore those trades of $8 after the close. Before the open LGND is at 8 1/2 X 8 5/8.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News